CJC-1295

Product name : CJC-1295

CAS : 863288-34-0

Molecular Formula : C₁₅₉H₂₅₈N₄₆O₄₅

Product description :
CJC-1295 is a tetrasubstituted 30-amino acid peptide hormone, primarily functioning as a growth hormone releasing hormone (GHRH) analog. It was invented by ConjuChem, a Canadian biotechnology company.

One of the advantages of CJC-1295 over traditional GHRH or rHGH is its ability to bioconjugate with serum albumin, thus increasing its half-life and therapeutic window. It accomplishes this by using protecting groups around the amino acids of GHRH typically susceptible to enzymatic degradation.
ConjuChem initiated clinical trials for CJC-1295 during the mid-2000s. The objective of the drug was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous HGH are presumed to increase lipolysis (fat loss). The trial was ultimately successful for most research subjects, but the drug's marketing stalled when three of the trial's patients suffered a myocardial infarction.